KARO BIO AND WYETH COLLABORATION - TARGETS INFLAMMATION
Karo Bio and Wyeth Pharmaceuticals have a drug discovery collaboration with the liver X receptor (LXR) as pharmaceutical target. LXR is a new member of the nuclear receptor protein family and the receptor plays important roles in cholesterol metabolism and inflammatory responses. The collaboration with Wyeth has primarily been focused on atherosclerosis but other clinical opportunities have also been explored. The continued collaboration will focus on drug discovery in the field of inflammatory diseases.
"Our collaboration with Wyeth has generated numerous compound series and a deepened understanding about LXR function in disease processes. Recently is has been shown that LXR is an important target for treatment of inflammatory disorders and we see exciting opportunities in the continued collaboration" says Per Olof Wallström, President of Karo Bio.
For further information, please contact:
Per Olof Wallström, President & Chief Executive Officer
Phone: +46 8 608 60 20
Per Otteskog, Senior Vice President
Phone: +46 8 608 60 18
About Karo Bio
Karo Bio is a drug discovery and development company specializing in nuclear receptors for the development of novel pharmaceuticals.
The Company has a project portfolio with innovative molecules that primarily targets metabolic diseases such as diabetes, atherosclerosis and dyslipidemia. In all of these areas there are significant market opportunities and a need for new pharmaceuticals with new mechanisms of action. Karo Bio intends to bring selected compounds within niche therapeutic areas into late stage clinical development and, potentially, to the market. In addition to pursuing niche opportunities, Karo Bio continues to develop compounds aimed at treatment of broad patient populations to clinical proof of concept before out-licensing.
In addition to the proprietary projects, Karo Bio has three strategic collaborations with international pharmaceutical companies for development of innovative therapies for the treatment of common diseases.
Karo Bio is listed on the OMX Nordic Exchange Stockholm AB since 1998 (Reuters: KARO.ST).
This press release is also available online at: www.karobio.com and www.newsroom.cision.com